jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

April. 22, 2023

Dec. 05, 2023

jRCT2031230051

Phase 2 Allergen Challenge Trial of NTa53 in Patients with Allergic Conjunctivitis

Phase 2 Conjunctival Allergen Challenge Trial of NTa53

Hasunuma Tomoko

Kitasato University Kitasato Institute Hospital

5-9-1 Shirokane,Minato-ku, Tokyo, Japan

+81-3-5791-6350

t-hasu@insti.kitasato-u.ac.jp

Research & Development

Nitto Medic Co., Ltd.

1-14-1 Yasuuchi, Yatsuo-machi, Toyama-city, Toyama, Japan

+81-76-455-3541

clinical@nittomedic.co.jp

Complete

June. 20, 2023

June. 20, 2023
40

Interventional

randomized controlled trial

double blind

dose comparison control

crossover assignment

treatment purpose

-Japanese adult between the age of 18 to under 65 years at the time of the informed consent
-Specific IgE positive against cedar pollen allergens
-Other protocol-specified inclusion criteria may apply

-Eye disease other than allergic conjunctivitis is present and requires treatment.
-Other protocol-specified exclusion criteria may apply

18age old over
65age old not

Both

Allergic Conjunctivitis

NTa53 and placebo administration, and allergen challenge

Efficacy (Subjective Ocular Symptom Score and Objective Findings Score), Safety

Nitto Medic Co., Ltd.
The IRB of Kitasato University Shirokane Campus
5-9-1 Shirokane,Minato-ku, Tokyo

+81-3-5791-6177

irb-pt@insti.kitasato-u.ac.jp
Approval

April. 14, 2023

No

none

History of Changes

No Publication date
4 Dec. 05, 2023 (this page) Changes
3 July. 11, 2023 Detail Changes
2 June. 25, 2023 Detail Changes
1 April. 22, 2023 Detail